Feedback
Settings

Settings

Goto Application

658,469 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 65,847
1.WO/2025/227692SERS BIOSENSOR BASED ON CRISPR/CAS13A SYSTEM AND USE THEREOF
WO - 06.11.2025
Int.Class C12Q 1/682
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
682Signal amplification
 Appl.No PCT/CN2024/135334 Applicant NANJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS Inventor SONG, Chunyuan
Disclosed are an SERS biosensor based on a CRISPR/Cas13a system and use thereof. The SERS biosensor comprises an SERS sensing chip, a first reagent, a second reagent, a third reagent, and a fourth reagent. The SERS sensing chip is a silver nanorod array substrate with a surface modified with a hairpin-type DNA single chain H1 and a closed molecule 6-mercaptohexanol. The first reagent is an SERS probe and a buffer thereof. The second reagent is a hairpin-type nucleic acid aptamer chain MUC1-apt aqueous solution. The third reagent is a CRISPR/Cas13a system and a buffer thereof. The fourth reagent is a hairpin-type DNA single-chain H2 aqueous solution. The reagents and a gastric cancer exosome sample to be detected are mixed and then dropwise added to the surface of the SERS sensing chip, and sensitive and accurate detection of gastric cancer-related exosomes is achieved by means of the CRISPR/Cas13a system, catalytic hairpin assembly, and SERS enhancement performance of the silver nanorod array substrate.
2.WO/2025/230707ADAPTIVE CROSSTALK COMPENSATION OF OPTICAL SIGNAL DETECTION
WO - 06.11.2025
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
 Appl.No PCT/US2025/024409 Applicant GEN-PROBE INCORPORATED Inventor CHABOT, Vincent
Systems, methods, computers, and instruments programmed with software to compensate for fluorescence crosstalk from one channel of a fluorometer into a different channel of the fluorometer during nucleic acid amplification. An adaptive crosstalk compensation factor specific for a paired set of Emitter channel and Receiver channel amplification run curves can be calculated and used to reduce false-positive errors.
3.WO/2025/231172MODULAR RNA-BASED RNA SENSORS UTILIZING ADAR EDITING
WO - 06.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/027160 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor GAO, Xiaojing
A method for expressing a protein in a target cell, the method including: combining the target cell with a sensor RNA including the following: (i) a first nucleotide sequence including a sensor nucleotide sequence including: (a) a first region that is reverse complementary to the target RNA, (b) a second region including a stem-loop sequence including one or more editable codons wherein a first portion of the stem-loop sequence is reverse complementary to a sequence in the sensor RNA, and (c) a third region that is reverse complementary to the target RNA, and (ii) a second nucleotide sequence encoding a first cleavage domain, and (iii) a third nucleotide sequence encoding an output protein; wherein the target RNA is present in the target cell.
4.WO/2025/230706IMMUNE CHECKPOINT INHIBITORS FOR USE IN CARDIAC REPAIR
WO - 06.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/024363 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor QIN, Juan
Methods of using inhibitors of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for treating heart disease are provided. In addition, methods are provided for screening candidate agents for inhibition of CTLA-4 and effectiveness of candidate inhibitors of CTLA-4 in improving cardiac function, decreasing or preventing damage to the heart, including reducing chamber dilatation, ventricular remodeling, and/or amount of fibrotic scar tissue, and increasing survival.
5.WO/2025/227916COMPOSITION COMPRISING AFLIBERCEPT AND VARIANT THEREOF, RELATED METHOD THEREFOR, AND USE THEREOF
WO - 06.11.2025
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/CN2025/080151 Applicant QILU PHARMACEUTICAL CO., LTD. Inventor YU, Yue
Provided is a composition comprising Aflibercept and a variant thereof, wherein the variant is a truncated variant of the VEGF-binding moiety of Aflibercept, and the content of the truncated variant is less than or equal to about 20% by mass. Further provided are a pharmaceutical formulation comprising the described composition and a preparation method therefor. In addition, further provided are a detection method for the described variant and use thereof in quality inspection or quality control of an Aflibercept-containing product.
6.WO/2025/229401SYSTEMS AND METHODS FOR SCREENING OF BIOLOGICAL COMPONENTS
WO - 06.11.2025
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No PCT/IB2025/000197 Applicant CELLANOME, INC. Inventor ZARGARI -PARISET, Eloise
Described herein are methods and systems for utilizing the formation and degradation of hydrogel chambers to analyze biological components comprising guide RNA barcodes associated with one or more genetic modifications. A method for analyzing a biological component can include introducing the biological component into a fluidic device; in the fluidic device, encapsulating the biological component in a hydrogel chamber, wherein the biological component comprises a guide ribonucleic acid (RNA) molecule associated with a genetic modification of the biological component; and releasing the guide RNA molecule from the biological component.
7.WO/2025/228816METHOD OF TARGETED SEQUENCING FOR DIAGNOSIS
WO - 06.11.2025
Int.Class C12Q 1/6848
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
6848characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
 Appl.No PCT/EP2025/061356 Applicant MEDICOVER BIOTECH LTD Inventor KOUMBARIS, George
The invention relates to an in-vitro method of diagnosis, prognosis, treatment response control, response prediction, of a particular human disease comprising the steps of: • (i) with one or more human samples, selected from the group comprising, a blood sample from a subject, a plasma sample, a serum sample, a urine sample, or a buffy coat sample; • (ii) preparing a first and at least a second nucleic acid sequencing library from the nucleic acids present in said samples; • (iii) mixing the nucleic acid sequencing libraries which were prepared to create a first mixed nucleic acid sequencing library (MNAL), • (iv) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first mixed nucleic acid library (MNAL) thereby isolating a first subset of library nucleic acid molecules; • (v) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV 1); • (vi) hybridizing one or more TAC oligonucleotides from a second TAC oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules; • (vii) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2); • (viii) analyzing the putatively informative sequence variants (PISV2) thereby diagnosing, prognosing, controlling the response to a drug, for a particular human disease state.
8.WO/2025/228996METHOD FOR PERSONALIZED THERAPY OF CELIAC DISEASE
WO - 06.11.2025
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No PCT/EP2025/061729 Applicant DR. FALK PHARMA GMBH Inventor TEWES, Bernhard
The present invention relates to a method for selecting or adjusting a therapy regimen for a subject having been diagnosed with celiac disease, wherein the therapy regimen comprises at least the treatment of celiac disease by administering a therapeutically effective amount of at least one transglutaminase 2 (TG2) inhibitor to said subject, wherein selecting or adjusting the therapy regimen is based on human leukocyte antigen DQ haplotypes of said subject.
9.WO/2025/229221METHOD OF DETECTION OF METHYLMALONIC ACID (MMA) AND/OR A RELATED MMA COMPOUND
WO - 06.11.2025
Int.Class C12Q 1/25
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
25involving enzymes not classifiable in groups C12Q1/26-C12Q1/7097
 Appl.No PCT/EP2025/062150 Applicant WILLIAM OAK DIAGNOSTICS LIMITED Inventor PATTO, Alexander
A method of detecting methylmalonic acid (MMA) and/or a related MMA compound in a sample, is provided, comprising at least: (a) conversion of said MMA and/or related MMA compound under the catalysis of ACSF3 in a reaction mixture; and (b) detecting a component of the reaction mixture after step (a); and (c) using the result of step (b) to determine an amount of MMA or related MMA compound in the sample.
10.WO/2025/230151PATHOGEN-SPECIFIC PROBE SET FOR SIMULTANEOUSLY DETECTING PATHOGENS CAUSING RESPIRATORY SYNDROME AND USE THEREOF
WO - 06.11.2025
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/KR2025/004354 Applicant KOREA DISEASE CONTROL AND PREVENTION AGENCY Inventor KIM, Eun Jin
The present invention relates to a pathogen-specific probe set capable of simultaneously detecting viruses and bacteria associated with respiratory syndromes, a composition for diagnosing respiratory syndrome comprising same, a kit for diagnosing respiratory syndrome comprising same, and a method for simultaneously detecting respiratory syndrome-associated viruses and bacteria using the probe set.
# -